Classes
DEA Class; Rx
Common Brand Names; Casodex
- Antineoplastics, Antiandrogen;
- CYP3A4 Inhibitor, Moderate
Description
Oral nonsteroidal antiandrogen
Used for the treatment of metastatic prostatic carcinoma
Can cause hepatotoxicity; monitor liver function tests
Indications
Contraindications
Hypersensitivity
Female patients (esp pregnant-may harm fetus)
Adverse Effects
- Hot flashes (53%)
- General pain (35%)
- Back pain (25%)
- Asthenia (22%)
- Constipation (22%)
- Pelvic pain (21%)
- Infection (18%)
- Nausea (15%)
- Dyspnea (13%)
- Edema (13%)
- Peripheral edema (13%)
- Diarrhea (12%)
- Hematuria (12%)
- Nocturia (12%)
- Abdominal pain (11%)
- Anemia (11%)
- Gynecomastia (9%)
- Rash (9%)
- UTI (9%)
- Chest pain (8%)
- Hypertension (8%)
- Vomiting (8%)
- Flu like symptoms (7%)
- Headache (7%)
- LFTs elevation (7%)
- Weight loss (7%)
- Anorexia (6%)
- Breast pain (6%)
- Anxiety (5%)
- Arthritis (5%)
Warnings
Hepatic impairment
Severe liver injury resulting in hospitalization or death reported
Spermatogenesi inhibition reported
Gynecomastia and breast pain reported during therapy when used as single agent
May reduce glucose tolerance in males when used in combination with LHRH; monitor blood glucose
Monitor prostate specific antigen (PSA) progression if PSA increases
Antiandrogen therapy may cause morphological changes in spermatozoa; based on findings in animal reproduction studies and its mechanism of action, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 130 days after administering final dose administered
Based on animal studies, therapy can lead to inhibition of spermatogenesis and may impair fertility in males of reproductive potential; long-term effects on male fertility not studied
Pregnancy and Lactation
Contraindicated for use in pregnant women because it can cause fetal harm; not indicated for use in females; there are no human data on use in pregnant women
Not indicated for use in pregnant women
Maximum Dosage
50 mg/day PO.
50 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Bicalutamide
tablet
- 50mg